Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
